ライフサイエンスコーパス: BTT

1 BTT also reacts with sulfur to form an oligomer/polymer

2 BTT patients incurred an increased risk of 1-year mortal

3 BTT reacts with lithium metal to form lithium 1,3,5-benz

4 BTT was more cost-effective at $205 to $272/disability-a

5 BTT(NDI)(3) self-assembles in apolar solvents into highl

6 BTT-1023 is a fully human monoclonal anti-VAP-1 antibody

7 BTT-VAD therapy is associated with improved survival and

8 y, in under flow conditions (90 dynes/cm(2)) BTT-3033, but not BTT-3034, inhibited collagen binding b

9 ased metal-organic framework Cr3 [(Cr4 Cl)3 (BTT)8 ]2 (Cr-BTT; BTT(3-) =1,3,5-benzenetristetrazolate)

10 hange of the guest Mn2+ ions in Mn3[(Mn4Cl)3(BTT)8(CH3OH)10]2 (1-Mn2+; BTT=1,3,5-benzenetristetrazola

11 -) enables formation of [Mn(DMF)6]3[(Mn4Cl)3(BTT)8(H2O)12]2.42DMF.11H2O.20CH3OH, featuring a porous m

12 and 1,3,5-tris(2H-tetrazol-5-yl)benzene (H(3)BTT), promoted by a urea derivative, leads to a highly p

13 t ambient temperatures, the M(3)[(M(4)Cl)(3)(BTT)(8)](2) (M-BTT; BTT(3-) = 1,3,5-benzenetristetrazola

14 nthesis and properties of Zn(3)[(Zn(4)Cl)(3)(BTT)(8)](2) (ZnZnBTT, BTT(3-) = 1,3,5-benzenetristetrazo

15 the general formula M(II)(3)[(M(II)(4)Cl)(3)(BTT)(8)](2), which adopts an anionic, sodalite-like stru

16 Following implant, 82% (BTT) and 80% (DT) of patients at 6 months and 79% (DT) a

17 A BTT strategy is more effective and cost-effective than a

18 Thirteen patients received MARS as a BTT, of which 9 were transplanted with a 1-year survival

19 HTX recipients undergoing LVAD implant as a BTT.

20 In the model, a BTT strategy treating adults with a 10-year CVD event ri

21 Thus, the binding sites for BTT-3033 and BTT-3034 are differentially available in distinct integr

22 imilar sulfonamide derivatives, BTT-3033 and BTT-3034, and show that, under static conditions, they h

23 LVADs were implanted as BTT in 30 patients.

24 he primary outcomes were implant strategy as BTT and subsequent transplant by 2 years.

25 olyte additive, i.e., 1,3,5-benzenetrithiol (BTT), which is used to construct solid-electrolyte inter

26 In both BTT and DT cohorts, pre LVAD VAs were not associated wit

27 sustained improvements from baseline in both BTT and DT patients in median MLWHF scores (by 40 and 42

28 ntricular assist devices (LVAD) as a bridge (BTT) to heart transplantation (HTX) may be limited by th

29 materials with the formula Fe(y)Co(1-y)BTT (BTT = 1,3,5-benzenetrithiolate).

30 framework Cr3 [(Cr4 Cl)3 (BTT)8 ]2 (Cr-BTT; BTT(3-) =1,3,5-benzenetristetrazolate), featuring coordi

31 es, the M(3)[(M(4)Cl)(3)(BTT)(8)](2) (M-BTT; BTT(3-) = 1,3,5-benzenetristetrazolate) series of framew

32 When patients were stratified by BTT status and the presence of risk factors, including a

33 gned C(3)-symmetric disc-shaped chromophore, BTT(NDI)(3), features electron accepting naphthalene dii

34 In static conditions BTT-3034, but not BTT-3033, inhibited collagen binding b

35 ganic framework Cr3 [(Cr4 Cl)3 (BTT)8 ]2 (Cr-BTT; BTT(3-) =1,3,5-benzenetristetrazolate), featuring c

36 red spectroscopy studies of Mn-, Fe-, and Cu-BTT, allowing the thermodynamics of H(2) adsorption to b

37 tructurally similar sulfonamide derivatives, BTT-3033 and BTT-3034, and show that, under static condi

38 thalene diimides linked to an electron donor BTT core.

39 -dicarboxylic acid bis-(2-butyloctyl) ester (BTT) and 4,8-bis(2-butyloctyl)benzo[1,2-b:4,5-b']dithiop

40 to evaluate survival benefits and costs for BTT-VAD versus nonbridged heart transplant recipients.

41 rovides poor discrimination of mortality for BTT patients and only modest discrimination for DT patie

42 ps for patients implanted for DT but not for BTT.

43 Parameters for BTT listing were estimated using logistic regression wit

44 roups was 8%, 7%, and 16%, respectively, for BTT patients; 9%, 12%, and 19%, respectively, for DT pat

45 Thus, the binding sites for BTT-3033 and BTT-3034 are differentially available in di

46 gers a unidirectional electron transfer from BTT to NDI and results in (BTT(*+)-NDI(*-)) lifetimes th

47 Over a 20-year time horizon, BTT-VAD therapy increased survival at an increased cost

48 ly induced synovitis were imaged with (123)I-BTT-1023 SPECT/CT.

49 Clinical (124)I-BTT-1023 PET studies with injected radioactivity of 0.5-

50 estimated human effective dose due to (124)I-BTT-1023 was 0.55 mSv/MBq, if blockage of thyroid uptake

51 Human radiation dose estimates for (124)I-BTT-1023 were extrapolated.

52 nging from 0.54 to 0.58 for the HeartMate II BTT and DT groups, respectively.

53 ron transfer from BTT to NDI and results in (BTT(*+)-NDI(*-)) lifetimes that are by up to 3 orders of

54 proach that employs a DNA-conjugated ligand (BTT-DNA) to localize and concentrate copper ions at the

55 l large-scale afforestation initiatives like BTT.

56 ratures, the M(3)[(M(4)Cl)(3)(BTT)(8)](2) (M-BTT; BTT(3-) = 1,3,5-benzenetristetrazolate) series of f

57 line with results from previously reported M-BTT frameworks.

58 ns in Mn3[(Mn4Cl)3(BTT)8(CH3OH)10]2 (1-Mn2+; BTT=1,3,5-benzenetristetrazolate) with selected cations

59 In static conditions BTT-3034, but not BTT-3033, inhibited collagen binding by an alpha2 varian

60 onditions (90 dynes/cm(2)) BTT-3033, but not BTT-3034, inhibited collagen binding by an alpha2 varian

61 al, we elucidate how CO(2) binds to a novel "BTT-type" metal-organic framework (MOF) featuring open m

62 The action of BTT-3033, unlike that of BTT-3034, was dependent on Tyr-

63 ysis estimated a 59%, 54%, and 43% chance of BTT-VAD therapy being cost-effective for high-, medium-,

64 The comparative effectiveness of BTT was robust to uncertainties in CVD risk estimation a

65 estimates were used to assess the impact of BTT on 1- and 5-year mortality.

66 present study were to evaluate the impact of BTT with LVAD on posttransplantation survival, to descri

67 center was associated with increased odds of BTT intent at implant and subsequent transplant receipt

68 ciated with a 79% increased adjusted odds of BTT LVAD designation (odds ratio, 1.79; 95% CI, 1.35-2.3

69 Only photoexcitation of BTT in the BTT(NDI)(3) polymers triggers a unidirectiona

70 The action of BTT-3033, unlike that of BTT-3034, was dependent on Tyr-285.

71 ng CHO cell adhesion to collagen I, but only BTT-3033 blocks platelet attachment under flow (90 dynes

72 odds ratio of 1-year mortality for patients BTT with LVAD compared with those with medical managemen

73 Radioiodinated BTT-1023 cleared rapidly from blood circulation and dist

74 y, we preclinically evaluated radioiodinated BTT-1023 for inflammation imaging.

75 The radioiodinated BTT-1023 was able to detect mild inflammation in vivo.

76 e intravenously injected with radioiodinated BTT-1023.

77 and hole delocalization along the respective BTT and NDI stacks.

78 patients, with 1-year mortality in high-risk BTT patients at 17.6% compared with 10.4% in high-risk m

79 Device [Thoratec Corporation]) for the same BTT indication in the same time period.

80 market approval, actual patient care setting BTT population support the original findings from the pi

81 In model-based analyses, a simple BTT strategy was more effective and cost-effective than

82 The BTT strategy recommended treatment to fewer people at hi

83 to variations in the age range analyzed, the BTT treatment threshold, or rates of treatment access, a

84 association between VAs and mortality in the BTT and DT populations.

85 In the BTT population, early post-LVAD VAs were not statistical

86 Only photoexcitation of BTT in the BTT(NDI)(3) polymers triggers a unidirectional electron

87 However, the superiority of the BTT strategy for averting microvascular complications is

88 ot change the comparative superiority of the BTT strategy, nor did titrating treatment using fasting

89 Compared with the TTT strategy, the BTT strategy would be expected to avert 24.4-30.5% more

90 ower risk of diabetes complications-than the BTT.

91 However, if insulin were unavailable, the BTT strategy would no longer be superior for preventing

92 only accepted willingness-to-pay thresholds, BTT-VAD therapy is likely to be cost-effective relative

93 Brainstem transmission time (BTT), which represents the time required for a neural st

94 n VAs and mortality in bridge to transplant (BTT) and destination therapy (DT) LVAD patients, separat

95 g longer with MCSs for bridge to transplant (BTT) and destination therapy (DT).

96 Device in the ADVANCE bridge to transplant (BTT) trial and continued access protocol were reviewed.

97 California) LVAD as a bridge to transplant (BTT, n = 486) and DT (n = 638) and 114 DT patients with

98 sist device (LVAD) for bridge-to-transplant (BTT) intent at an LVAD-only center.

99 nton, California) bridge to transplantation (BTT) (n = 281) and destination therapy (DT) (n = 374) tr

100 Bridge to transplantation (BTT) with left ventricular assist devices (LVADs) is a m

101 ALF patients as a bridge to transplantation (BTT), and as definitive therapy for toxic ingestion or i

102 he HM II LVAD for bridge to transplantation (BTT).

103 ffectiveness of a bridge-to-transplantation (BTT)-VAD approach relative to direct heart transplantati

104 target, a benefit-based tailored treatment (BTT) strategy emphasizing lowering CVD risk, or a hybrid

105 ]), with a benefit-based tailored treatment (BTT) strategy, aiming to lower estimated risk for compli

106 tion efforts under the Billion Tree Tsunami (BTT) project.

107 The Li-S cell with BTT delivers a specific discharge capacity of 1,239 mAh

108 A Li-S pouch cell with BTT is also evaluated to prove the concept.

109 (CP) materials with the formula Fe(y)Co(1-y)BTT (BTT = 1,3,5-benzenetrithiolate).

110 of Zn(3)[(Zn(4)Cl)(3)(BTT)(8)](2) (ZnZnBTT, BTT(3-) = 1,3,5-benzenetristetrazolate), a heretofore un